Background Medication practice in a hospital organization may be considered a process. As the efficiency of this process increases, the success of treatment and prophylaxis at a hospital is enhanced. Surveillance mechanisms for monitoring the medication process, such as pharmacovigilance, are new requirements that must be implemented. Organizational management methods, such as process modeling, assist the effective implementation of improvements, and, thus, it is believed that these methods should be used to improve the medication process. Objective The objective of this study was to present a case of model application for the drug distribution and dispensing process in a surgical center of a large Brazilian hospital, to comply with a new federal regulation. Design A case study was conducted at a tertiary university hospital. To perform the comparison between theory and practice based on the state‐of‐the‐art of the theme, on‐site observation, document analysis, and interviews with business managers were performed to collect data. Results Process modeling enabled characterization of the current drug distribution and dispensing process in the surgical unit. The improvement proposal design considered the current limitations and opportunities for improvement identified in the current situation. The presented proposal enables the implementation of legal requirements for drug traceability. Conclusions The use of modeling to redesign the process was of great assistance for the development and evaluation of the required changes. Modeling promoted a wide discussion of the current process and the improvement proposal, reducing the risk of failure when implementing the new work process. Copyright © 2016 John Wiley & Sons, Ltd.
Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased prevalence of clopidogrel hyporesponsiveness. To assess this, we genotyped CYP2C19, ABCB1, and PON1 in 187 patients who underwent percutaneous coronary intervention. Race was self-defined by patients. We also performed light transmission aggregometry with adenosine diphosphate (ADP) and arachidonic acid during dual antiplatelet therapy. We found a significant difference for presence of the CYP2C19*2 polymorphism between white and non-white patients. Although 7% of patients had platelet resistance to clopidogrel, this did not correlate with any of the tested genetic polymorphisms. We did not find platelet resistance to aspirin in this cohort. Multivariate analysis showed that patients with PON1 and CYP2C19 polymorphisms had higher light transmission after ADP aggregometry than patients with native alleles. There was no preponderance of any race in patients with higher light transmission aggregometry. In brief, PON1 and CYP2C19 polymorphisms were associated with lower clopidogrel responsiveness in this sample. Despite differences in CYP2C19 polymorphisms across white and non-white patients, genetic admixture by itself was not able to identify clopidogrel hyporesponsiveness.
Gene expression profiling by cDNA microarrays during murine thymus ontogeny has contributed to dissecting the large-scale molecular genetics of T cell maturation. Gene profiling, although useful for characterizing the thymus developmental phases and identifying the differentially expressed genes, does not permit the determination of possible interactions between genes. In order to reconstruct genetic interactions, on RNA level, within thymocyte differentiation, a pair of microarrays containing a total of 1,576 cDNA sequences derived from the IMAGE MTB library was applied on samples of developing thymuses (14-17 days of gestation). The data were analyzed using the GeneNetwork program. Genes that were previously identified as differentially expressed during thymus ontogeny showed their relationships with several other genes. The present method provided the detection of gene nodes coding for proteins implicated in the calcium signaling pathway, such as Prrg2 and Stxbp3, and in protein transport toward the cell membrane, such as Gosr2. The results demonstrate the feasibility of reconstructing networks based on cDNA microarray gene expression determinations, contributing to a clearer understanding of the complex interactions between genes involved in thymus/thymocyte development.
Introdução:A prevenção secundária após intervenção coronária percutânea (ICP) é fundamental para melhorar a sobrevida livre de eventos e consiste principalmente no controle de fatores de risco. Analisou-se a prevenção secundária de pacientes de alto risco, incluídos prospectivamente no estudo Sequence Variation in Platelet Aggregation in Response to Clopidogrel and aspirin (SPARC). Métodos: Foram arrolados 187 pacientes consecutivos entre dezembro de 2009 e fevereiro de 2011, tratados por ICP com stent e avaliados em retornos ambulatoriais de 30 dias, três meses, seis meses, e 12 meses quanto ao controle de hipertensão arterial, disglicemia, dislipidemia e tabagismo, e medidas terapêuticas respectivas. Resultados: Houve aumento significativo de pacientes com controle pressórico (29%; P = 0,02), que cessaram tabagismo (18%; P = 0,003), e que receberam hipolipemiantes (19%; P < 0,0001) entre a internação para ICP e o primeiro retorno após o ABSTRACT Background: Secondary prevention after percutaneous coronary intervention (PCI) is essential to increase event-free survival and consists mainly in risk factor control. We analyzed the secondary prevention of high-risk patients included prospectively in the Sequence Variation in Platelet Aggregation in Response to Clopidogrel and aspirin trial (SPARC). Methods: From December 2009 to February 2011 we enrolled 187 consecutive patients who were submitted to PCI with stent implantation and were evaluated in outpatient visits at 1, 3, 6, and 12 months of follow-up for the control of hypertension, dysglycemia, hyperlipidemia and smoking and their respective therapeutic measures. Results: There was a significant increase in the number of patients with controlled hypertension (29%; P = 0.02), who stopped smoking (18%; P = 0.003), and received statins (19%; P < 0.0001) between the index PCI and the first follow-up visit. The risk factor control improvement led to a decrease in the mean Framingham risk score (9.9%; P < 0.0001). During the 12 months follow-up the gains achieved at PCI admission were maintained for all risk factors. Conclusions: An important effect was observed on the index PCI admission with increased prescription of risk factor Original Article
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.